Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COMPASS Pathways plcCMPS · Entity 4567 | Chief Financial Officer | February 02, 2023 | February 03, 2023 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, CFO & Treasurer | January 24, 2018 | January 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COMPASS Pathways plc
Report date February 02, 2023 · Filed February 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 22,500 |
Reported balance
After 2023-02-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-02 · Grant · Acquired 22,500 · Balance 22,500 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on February 2, 2024. |
| Share Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2033-02-01 | Direct | 45,000 |
Reported balance
After 2023-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-02 · Grant · Acquired 45,000 · Balance 45,000 F3: The share option shall vest in forty-eight equal monthly installments beginning on March 2, 2023. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on February 2, 2024.
F3: The share option shall vest in forty-eight equal monthly installments beginning on March 2, 2023.
Karyopharm Therapeutics Inc.
Report date January 24, 2018 · Filed January 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.45 · Expires 2028-01-23 | Direct | 95,000 |
Reported balance
After 2018-01-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-24 · Grant · Acquired 95,000 · Balance 95,000 F1: This option was granted on January 24, 2018. The shares underlying this option vest as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 24, 2018. The shares underlying this option vest as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2023 Filed Feb 3, 2023 21:25 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantShare Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001816590-23-000016 · wf-form4_167545948442433.xml · derivative · entry 2 FALVEY MICHAEL · CIK 0001286197 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Ordinary Shares · 45,000 shares Expires 2033-02-01 F3 · derivative.exercise_date: The share option shall vest in forty-eight equal monthly installments beginning on March 2, 2023. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 21:25 UTC | COMPASS Pathways plc CMPS · Entity 4567 | GrantOrdinary Shares | 22,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001816590-23-000016 · wf-form4_167545948442433.xml · nonDerivative · entry 1 FALVEY MICHAEL · CIK 0001286197 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · shares: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on February 2, 2024. F2 · price: Represents an award of Restricted Share Units ("RSUs") granted under the Issuer's 2020 Share Option and Incentive Plan. Each RSU represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments, with the first installment vesting on February 2, 2024. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 16:30 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $10.45 | $0.00 |
DisclosureSEC source: 0001209191-18-005381 · doc4.xml · derivative · entry 1 FALVEY MICHAEL · CIK 0001286197 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option was granted on January 24, 2018. The shares underlying this option vest as to 25% of the shares on January 24, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 11, 2017 Filed Sep 13, 2017 16:09 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantNonstatutory Stock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001209191-17-052585 · doc4.xml · derivative · entry 1 FALVEY MICHAEL · CIK 0001286197 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2027-09-10 F1 · derivative.exercise_date: This option was granted on September 11, 2017. The shares underlying this option vest as to 25% of the shares on September 11, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.